(5-Methoxy-1,2-dimethyl-4,7-dioxoindol-3-yl)methyl (4-nitrophenyl) carbonate | 930285-79-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (5-Methoxy-1,2-dimethyl-4,7-dioxoindol-3-yl)methyl (4-nitrophenyl) carbonate
• CAS: 930285-79-3
• 化学式: C₁₉H₁₆N₂O₈
• 分子量: 400.345
• InChiKey: SKYSJWIDWNFVDV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  130
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  诺氟沙星 、 (5-Methoxy-1,2-dimethyl-4,7-dioxoindol-3-yl)methyl (4-nitrophenyl) carbonate 在 吡啶 作用下， 以 N,N-二甲基甲酰胺 、 叔丁醇 为溶剂， 反应 24.0h， 以18 mg的产率得到
  参考文献：
  名称：

  [EN] PYRROLOBENZODIAZEPINE PRODRUGS AND ANTIBODY CONJUGATES THEREOF
  [FR] PROMÉDICAMENTS DE PYRROLOBENZODIAZÉPINE ET CONJUGUÉS D'ANTICORPS DE CEUX-CI

  摘要：

  这项发明涉及具有谷胱甘肽活化二硫键前药基团、DT-二氢呋喃酮酶活化醌前药基团或活化氧化物种的芳基硼酸或芳基硼酯前药基团的吡咯苯并二氮杂环烷单体和二聚体前药。该发明还涉及吡咯苯并二氮杂环烷前药二聚体-抗体共轭物。

  公开号：

  WO2018031662A1
• 作为产物：
  描述：

  ethyl acetoacetate N-methylimine 在 盐酸 、 tin 、 lithium aluminium tetrahydride 、 硝酸 、 溶剂黄146 、 N,N-二异丙基乙胺 、 potassium hydroxide 作用下， 以 四氢呋喃 、 硝基甲烷 、 乙醇 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 49.0h， 生成 (5-Methoxy-1,2-dimethyl-4,7-dioxoindol-3-yl)methyl (4-nitrophenyl) carbonate
  参考文献：
  名称：

  [EN] PYRROLOBENZODIAZEPINE PRODRUGS AND ANTIBODY CONJUGATES THEREOF
  [FR] PROMÉDICAMENTS DE PYRROLOBENZODIAZÉPINE ET CONJUGUÉS D'ANTICORPS DE CEUX-CI

  摘要：

  这项发明涉及具有谷胱甘肽活化二硫键前药基团、DT-二氢呋喃酮酶活化醌前药基团或活化氧化物种的芳基硼酸或芳基硼酯前药基团的吡咯苯并二氮杂环烷单体和二聚体前药。该发明还涉及吡咯苯并二氮杂环烷前药二聚体-抗体共轭物。

  公开号：

  WO2018031662A1

文献信息

• Bioreduction activated prodrugs of camptothecin: molecular design, synthesis, activation mechanism and hypoxia selective cytotoxicity
  作者：Zhouen Zhang、Kazuhito Tanabe、Hiroshi Hatta、Sei-ichi Nishimoto

  DOI：10.1039/b502813b

  日期：——

  Several water-soluble derivatives (CPT3, CPT3a–d) of camptothecin (CPT) were synthesized, among which CPT3 bearing an N,N′-dimethyl-1-aminoethylcarbamate side-chain was further conjugated with reductively eliminating structural units of indolequinone, 4-nitrobenzyl alcohol and 4-nitrofuryl alcohol to produce novel prodrugs of camptothecin (CPT4–6). All CPT derivatives were of lower cytotoxicity than their parent compound of CPT. In contrast, CPT4 and CPT6 showed higher hypoxia selectivity of cytotoxicity towards tumor cells than CPT. A mechanism by which a representative prodrug CPT4 is activated in the presence of DT-diaphorase to release CPT was also discussed. The bioreduction activated CPT prodrugs including CPT4 and CPT6 are identified to be promising for application to the hypoxia targeting tumor chemotherapy.

  合成了几种水溶性喜树碱衍生物(CPT3、CPT3a-d)，其中带有N,N′-二甲基-1-氨基乙基氨基甲酸酯侧链的CPT3进一步与吲哚醌、4-硝基苄醇和4-硝基糠醇的可还原消除结构单元偶联，产生了新的喜树碱前药(CPT4-6)。所有CPT衍生物的细胞毒性都低于其母体化合物CPT。相比之下，CPT4和CPT6对肿瘤细胞的缺氧选择性细胞毒性高于CPT。还讨论了一种代表性前药CPT4在存在DT-二氢酶的条件下释放CPT的激活机制。包括CPT4和CPT6在内的生物还原激活的CPT前药被认为有望应用于靶向缺氧肿瘤的化疗。
• [EN] BIOREDUCTIVELY-ACTIVATED PRODRUGS<br/>[FR] PROMÉDICAMENTS ACTIVÉS PAR UNE BIORÉDUCTION
  申请人：ANGIOGENE PHARM LTD

  公开号：WO2006032921A1

  公开（公告）日：2006-03-30

  The present invention relates to a compound of formula (1), or a pharmaceutically acceptable salt thereof, Formula: (1); wherein: R1 is a substituted aryl or heteroaryl group bearing at least one nitro or azido group or is an optionally substituted benzoquinone, optionally substituted naphthoquinone or optionally substituted fused heterocycloquinone; R2 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, aryl or heteroaryl; and R3 is selected such that R3NH2 represents a cytotoxic nucleoside analogue or an ester or phosphate ester prodrug of a cytotoxic nucleoside analogue, with the proviso that if R1 is an aryl group then R2 is not H.

  本发明涉及一种具有如下式（1）的化合物，或其药学上可接受的盐，式中：R1是带有至少一个硝基或偶氮基的取代芳基或杂环芳基，或者是可选择取代的苯醌、可选择取代的萘醌或可选择取代的融合杂环喹啉；R2是H、可选择取代的烷基、可选择取代的烯基、可选择取代的炔基、可选择取代的环烷基、可选择取代的杂环烷基、芳基或杂环芳基；R3被选择为R3NH2，表示细胞毒性核苷类似物或细胞毒性核苷类似物的酯或磷酸酯前药，但如果R1是芳基，则R2不是H。
• Indolequinone Antitumor Agents:  Correlation between Quinone Structure and Rate of Metabolism by Recombinant Human NAD(P)H:Quinone Oxidoreductase. Part 2
  作者：Elizabeth Swann、Paola Barraja、Ann M. Oberlander、Walter T. Gardipee、Anna R. Hudnott、Howard D. Beall、Christopher J. Moody

  DOI：10.1021/jm010884c

  日期：2001.9.1

  A series of indolequinones bearing various functional groups has been synthesized, and the effects of substituents on the metabolism of the quinones. by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) were studied. Indolequinones were selected for study on the basis of the X-ray crystal structure of the human enzyme, and were designed to probe the effect of substituents particularly at N-1. Metabolism of the quinones. by NQO1 revealed that, in general, compounds with electron-withdrawing groups at the indole 3-position were among the best substrates, and that groups larger than methyl at N-1 are clearly tolerated. Compounds with a leaving group at the 3-indolyl methyl position generally inactivated the enzyme. The toxicity toward human colon carcinoma cells with either no detectable activity (BE-WT) or high NQO1 activity (BE-NQ) was also studied in representative quinones. The most toxic compounds were those with a leaving group at the C-3 position; these compounds were 1.1-5.3-fold more toxic. to the BE-NQ than the BE-WT cells.
• [EN] PYRROLOBENZODIAZEPINE PRODRUGS AND ANTIBODY CONJUGATES THEREOF<br/>[FR] PROMÉDICAMENTS DE PYRROLOBENZODIAZÉPINE ET CONJUGUÉS D'ANTICORPS DE CEUX-CI
  申请人：GENENTECH INC

  公开号：WO2018031662A1

  公开（公告）日：2018-02-15

  The invention relates generally to pyrrolobenzodiazepine monomer and dimer prodrugs having a glutathione-activated disulfide prodrug moiety, a DT-diaphorase-activated quinone prodrug moiety or a reactive oxygen species-activated aryl boronic acid or aryl boronic ester prodrug moiety. The invention further relates to pyrrolobenzodiazepine prodrug dimer-antibody conjugates.

  这项发明涉及具有谷胱甘肽活化二硫键前药基团、DT-二氢呋喃酮酶活化醌前药基团或活化氧化物种的芳基硼酸或芳基硼酯前药基团的吡咯苯并二氮杂环烷单体和二聚体前药。该发明还涉及吡咯苯并二氮杂环烷前药二聚体-抗体共轭物。